Cargando…

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus

OBJECTIVE: To evaluate the effects and side effects of both inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). METHODS: This was a prospective, single-center, observational study. Patients with SLE planning to receive COVID-19 vaccines were recruited and matc...

Descripción completa

Detalles Bibliográficos
Autores principales:	So, Ho, Li, Tena, Chan, Vivien, Tam, Lai-Shan, Chan, Paul KS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021484/ https://www.ncbi.nlm.nih.gov/pubmed/35464809 http://dx.doi.org/10.1177/1759720X221089586

Ejemplares similares

Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
por: Mormile, Ilaria, et al.
Publicado: (2022)

Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
por: Lim, Wey Wen, et al.
Publicado: (2021)

Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis
por: Ramirez, Giuseppe A., et al.
Publicado: (2022)

Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis
por: Huang, Yafang, et al.
Publicado: (2016)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
por: Garcia-Cirera, Silvia, et al.
Publicado: (2022)

Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis
por: Teixeira, Vítor, et al.
Publicado: (2018)

Exacerbation of Lupus Erythematosus Panniculitis After Administration of COVID-19 mRNA Vaccine
por: Avcı, Ceylan, et al.
Publicado: (2022)

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years
por: Soybilgic, Arzu, et al.
Publicado: (2013)

Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis
por: Liao, Zhengfa, et al.
Publicado: (2016)

Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus
por: Yu, Shui-Lian, et al.
Publicado: (2012)

Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
por: Niebel, Dennis, et al.
Publicado: (2021)

Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
por: Alesci, Alessio, et al.
Publicado: (2022)

Safety and immunogenicity of mRNA COVID‐19 vaccine in inpatients with muscular dystrophy
por: Saito, Tomoko, et al.
Publicado: (2022)

New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination
por: Báez-Negrón, Laisha, et al.
Publicado: (2022)

Subacute cutaneous lupus erythematosus after mRNA-based SARS-CoV-2 vaccination
por: Rimmer, Sarah, et al.
Publicado: (2023)

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
por: Nurpeisova, Ainur, et al.
Publicado: (2022)

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
por: Yang, Lei, et al.
Publicado: (2023)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
por: Lee, Jisun, et al.
Publicado: (2023)

ODP514 Safety of Inactivated and mRNA COVID-19 Vaccination among Patients Treated for Hypothyroidism: a Population-based Cohort Study
por: Chui, Celine, et al.
Publicado: (2022)

Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
por: Bloomfield, Marketa, et al.
Publicado: (2021)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
por: Chan, Justin, et al.
Publicado: (2023)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity
por: Keshtkar-Jahromi, Maryam, et al.
Publicado: (2020)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Systemic Lupus Erythematosus and Immunodeficiency
por: Chan, Shirley Chiu Wai, et al.
Publicado: (2021)

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
por: Intapiboon, Porntip, et al.
Publicado: (2021)

Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab
por: Quartuccio, Luca, et al.
Publicado: (2023)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
por: Giuliano, Anna, et al.
Publicado: (2023)

1639. A Review of Clinical Safety, Reactogenicity, and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine (mRNA-1010) in Adults
por: Soens, Mieke, et al.
Publicado: (2023)

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
por: Cheng, Franco Wing Tak, et al.
Publicado: (2022)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
por: Provine, Nicholas M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rec04cpo1fr3u8dtg507mtc1qf